- Home
- AIDX vs PPCB Comparison
AIDX vs PPCB Comparison
Compare AIDX & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIDX | PPCB |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Precision Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.7M |
| IPO Year | 2025 | 2011 |
Fundamental Metrics
Financial Performance| Metric | AIDX | PPCB |
|---|---|---|
| Price | $0.23 | $1.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 129.2K | ★ 166.1K |
| Earning Date | 11-15-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.48 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,045,133.00 | N/A |
| Revenue This Year | $44.20 | N/A |
| Revenue Next Year | $95.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.71 | N/A |
| 52 Week Low | $0.23 | $0.06 |
| 52 Week High | $18.96 | $6.79 |
Technical Indicators
Market Signals| Indicator | AIDX | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 24.29 | 68.64 |
| Support Level | N/A | $1.23 |
| Resistance Level | $0.69 | $1.98 |
| Average True Range (ATR) | 0.02 | 0.16 |
| MACD | 0.00 | 0.21 |
| Stochastic Oscillator | 0.00 | 58.29 |
Price Performance
Historical ComparisonAbout AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.